Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

BACKGROUND: Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective vaccines are needed to protect this population, facilitate in-person learning and socializ...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:N Engl J Med
Main Authors: Frenck, Robert W., Klein, Nicola P., Kitchin, Nicholas, Gurtman, Alejandra, Absalon, Judith, Lockhart, Stephen, Perez, John L., Walter, Emmanuel B., Senders, Shelly, Bailey, Ruth, Swanson, Kena A., Ma, Hua, Xu, Xia, Koury, Kenneth, Kalina, Warren V., Cooper, David, Jennings, Timothy, Brandon, Donald M., Thomas, Stephen J., Türeci, Özlem, Tresnan, Dina B., Mather, Susan, Dormitzer, Philip R., Şahin, Uğur, Jansen, Kathrin U., Gruber, William C.
פורמט: Artigo
שפה:Inglês
יצא לאור: Massachusetts Medical Society 2021
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8174030/
https://ncbi.nlm.nih.gov/pubmed/34043894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2107456
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים